BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 32657150)

  • 1. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
    Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
    Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
    Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
    Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
    Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK
    J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
    Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
    Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.
    Mattar CNZ; Gil-Farina I; Rosales C; Johana N; Tan YYW; McIntosh J; Kaeppel C; Waddington SN; Biswas A; Choolani M; Schmidt M; Nathwani AC; Chan JKY
    Mol Ther; 2017 Aug; 25(8):1843-1853. PubMed ID: 28462816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
    Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
    Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
    Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
    J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and improved AAVenues: current status of hemophilia B gene therapy.
    Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
    Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.
    Vercauteren K; Hoffman BE; Zolotukhin I; Keeler GD; Xiao JW; Basner-Tschakarjan E; High KA; Ertl HC; Rice CM; Srivastava A; de Jong YP; Herzog RW
    Mol Ther; 2016 Jun; 24(6):1042-1049. PubMed ID: 27019999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
    Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
    Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.